Metabolic Peptides

Metabolic peptides represent a rapidly growing area of study. Tirzepatide is a dual GIP/GLP-1 agonist with significant published data on weight management and metabolic health. MOTS-C is a unique mitochondria-derived peptide that activates AMPK signaling for improved glucose metabolism. 5-Amino-1MQ inhibits NNMT for enhanced fat metabolism. Together these compounds offer multiple angles for studying metabolic dysfunction, obesity, and longevity.

Tirzepatide has produced remarkable weight reduction data in phase 3 clinical trials — up to 22.5% body weight reduction over 72 weeks. Its dual receptor action on both GLP-1 and GIP receptors produces superior metabolic outcomes compared to GLP-1 agonists alone. MOTS-C is unusual in that it is encoded within the mitochondrial genome and functions as a hormone-like signal that promotes metabolic flexibility and glucose uptake. 5-Amino-1MQ (5-amino-1-methylquinolinium) specifically inhibits NNMT, an enzyme that has been identified as a regulator of fat cell differentiation and adipogenesis.

Research into metabolic peptides is at the forefront of obesity medicine, metabolic disease treatment, and longevity science. These compounds target fundamental cellular energy regulation rather than simple caloric restriction pathways, representing a mechanistically distinct approach to metabolic research. All products in this category are available from Phiogen with independent COA verification and are sold for laboratory and educational use only, not for human therapeutic application.